货号：DT2025062120
CAS：1795134-78-9
规格：mg(更多包装需求请咨询客服)
纯度：≥98%
生产商：试剂家

生物活性：Toceranib-d8 is the deuterium labeled Toceranib. Toceranib (SU11654) is an orally active receptor tyrosine kinase (RTK) inhibitor, and it potently inhibits PDGFR, VEGFR, and Kit with Kis of 5 and 6 nM for PDGFRβ and Flk-1/KDR, respectively. Toceranib (SU11654) has antitumor and antiangiogenic activity, and used in the treatment of canine mast cell tumors[1][2].
体外研究(In Vitro)：Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].
试剂家 has not independently confirmed the accuracy of these methods. They are for reference only.
Toceranib-d8 相关抗体:
c-Kit Antibody (YA502)
Phospho-PDGFR beta (Y740) Antibody
VEGF Receptor 2 Antibody (YA014)
PDGFR alpha Antibody
VEGF Receptor 1 Antibody
VEGFA Antibody
VEGF Receptor2 Antibody
PDGF B Antibody (YA1556)
PLGF Antibody (YA1812)
PDGFR beta Antibody (YA1925)
VEGFD Antibody (YA2385)
Phospho-PDGFR beta (Tyr740) Antibody (YA3062)
c-Kit Antibody
SCF Antibody
PGF Antibody (YA1434)
Neuropilin 1 Antibody (YA1831)
VEGFB Antibody (YA2627)
分子量：404.51
Formula：C22H17D8FN4O2
CAS 号：1795134-78-9
非标记 CAS：356068-94-5
性状：固体
颜色：Light yellow to yellow
中文名称：托西尼布 d8
运输条件：Room temperature in continental US; may vary elsewhere.
储存方式：-20°C, protect from light, stored under nitrogen
*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)
纯度 & 产品资料
纯度： 99.08%
参考文献
[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.
 [Content Brief]
[2]. London CA, et al. Phase I dose-escalating study of SU11654, a small molecule receptor tyrosine kinase inhibitor, in dogs with spontaneous malignancies. Clin Cancer Res. 2003 Jul;9(7):2755-68.
 [Content Brief]
[3]. Halsey CH, et al. Development of an in vitro model of acquired resistance to toceranib phosphate (Palladia?) in canine mast cell tumor. BMC Vet Res. 2014 May 6;10:105.
 [Content Brief]
[4]. Mitchell L, et al. Clinical and immunomodulatory effects of toceranib combined with low-dose cyclophosphamide in dogs with cancer. J Vet Intern Med. 2012 Mar-Apr;26(2):355-62.
 [Content Brief]